Citations

Clear

151 citation(s) found for "Mathieu, D".

Impact of Cannabidiol on Myocardial Recovery in Patients with Acute Myocarditis: Rationale & Design of the ARCHER Trial
McNamara, Dennis M. , Arbel, Yaron, Bhimaraj, Arvind , Bocchi, Edimar Alcides , Kerneis, Matthieu, Liu, Peter P. , Parker, Andrea B., Smith, Eldon R., Tschöpe, Carsten , Group, ARCHER Study, Tschöpe, Carsten , Cooper, Leslie T. , Friedrich, Matthias G. , Kerneis, Mathieu , Tang, W.H. Wilson , Torre‐Amione, Guillermo , Group, ARCHER Study

Mayo Clinic

ESC Heart Failure | June 28, 2024 | Volume: 11 | Issue: 5 | Pages: 3416-3424

10.1002/ehf2.14889 | PMID 38937900 Get It

Abstract Aims Acute myocarditis, although a rare disease, can be associated with sudden cardiac death or the need for transplantation in both children and young adults. To date, there is no definitive evidence to support the routine use of immunosuppressive therapy or treatment targeting inflammation in patients with myocarditis. Animal models of cardiovascular (CV), as well as neurological diseases, have demonstrated that cannabidiol has significant anti-inflammatory properties and may represent a promising therapy in acute myocarditis. This efficacy has been shown in a murine model of autoimmune myocarditis as well as in in vitro and in vivo models of heart failure (HF). Methods and results We present the rationale and design of the ARCHER Trial, an international multicentre, double-blind, randomized, placebo-controlled, phase II study examining the safety and efficacy of a pharmaceutically produced cannabidiol formulation, in patients with mild to moderate acute myocarditis. Eligible patients are those with acute myocarditis, randomized within 10 days of the diagnostic cardiac MRI (CMR), which has met defined diagnostic criteria for myocarditis. Oral treatment (cannabidiol or placebo) is titrated from 2.5 mg/kg of body weight up to 10 mg/kg of body weight b.i.d. (or highest tolerated dose) and taken for 12 weeks in addition to standard of care therapy for HF. The primary endpoints are defined as changes in global longitudinal strain (GLS) and extra cellular volume (ECV), measured by CMR at 12 weeks. Assuming 80% power, a 5% alpha risk and 25% missing CMR follow-up data at Week 12, 100 patients are required to demonstrate the desired treatment effect of 18%. The change in left ventricular ejection fraction (LVEF) from baseline to Week 12 was selected as the secondary endpoint. Additional exploratory endpoints include changes in hs-troponin, NT-proBNP, markers of inflammation and endothelial function during the 12-week treatment period. The trial is ongoing but is now more than 50% recruited. As enrolment in the trial continues, no interim data are available for inclusion in this Design paper. Conclusions The ongoing ARCHER Trial is an international, multicentre, double-blind, randomized, placebo-controlled phase II study, designed to determine the effect of a pharmaceutically produced cannabidiol formulation on CMR parameters in patients presenting with acute myocarditis. Enrolment of 100 patients is expected to conclude in Q3 2024. Study results will be available in early 2025.
International consensus on the management of large (≥20 mm) colorectal laterally spreading tumors: World Endoscopy Organization Delphi study
Rex, Douglas K. , Aihara, Hiroyuki , Bastiaansen, Barbara A.J. , Bechara, Robert , Bhatt, Amit , Bourke, Michael J. , Byeon, Jeong‐Sik , Chino, Akiko , Goldblum, John R. , Ho, Shiaw Hooi , Jung, Yunho , Kawachi, Hiroshi , Khashab, Mouen A., Khomvilai, Supakij , Messmann, Helmut , Mori, Yuichi, Nakanishi, Yukihiro , Ngamruengphong, Saowanee , Parra‐Blanco, Adolfo , Pinto, Rafael Castilho , Pioche, Mathieu , Pohl, Heiko , Rastogi, Amit , Repici, Alessandro , Sethi, Amrita , Suzuki, Noriko, Tanaka, Shinji , Vieth, Michael, Yokoi, Chizu , Saito, Yutaka , Renteln, Daniel von , Chino, Akiko , Chiu, Philip Wai Yan , Elkholy, Shaimaa , Kawachi, Hiroshi , Yamamoto, Hironori , Yang, Dong-Hoon , Saito, Yutaka , Bhatt, Amit , Bechara, Robert , Djinbachian, Roupen , Chiu, Han‐Mo , Fukami, Norio , Bhandari, Pradeep , Cardoso, Daniela, Dekker, Evelien , Draganov, Peter V. , Emura, Fabian , Haji, Amyn , Khashab, Mouen A. , Kim, Eun Ran , Maselli, Roberta , Moons, Leon M.G. , Pellisé, Maria , Singh, Rajvinder

Mayo Clinic

Digestive Endoscopy | June 27, 2024 | Volume: 36 | Issue: 11 | Pages: 1253-1268

10.1111/den.14826 | PMID 38934243 Get It

ObjectivesThere have been significant advances in the management of large (≥20 mm) laterally spreading tumors (LSTs) or nonpedunculated colorectal polyps; however, there is a lack of clear consensus on the management of these lesions with significant geographic variability especially between Eastern and Western paradigms. We aimed to provide an international consensus to better guide management and attempt to homogenize practices.MethodsTwo experts in interventional endoscopy spearheaded an evidence‐based Delphi study on behalf of the World Endoscopy Organization Colorectal Cancer Screening Committee. A steering committee comprising six members devised 51 statements, and 43 experts from 18 countries on six continents participated in a three‐round voting process. The Grading of Recommendations, Assessment, Development and Evaluations tool was used to assess evidence quality and recommendation strength. Consensus was defined as ≥80% agreement (strongly agree or agree) on a 5‐point Likert scale.ResultsForty‐two statements reached consensus after three rounds of voting. Recommendations included: three statements on training and competency; 10 statements on preresection evaluation, including optical diagnosis, classification, and staging of LSTs; 14 statements on endoscopic resection indications and technique, including statements on en bloc and piecemeal resection decision‐making; seven statements on postresection evaluation; and eight statements on postresection care.ConclusionsAn international expert consensus based on the current available evidence has been developed to guide the evaluation, resection, and follow‐up of LSTs. This may provide guiding principles for the global management of these lesions and standardize current practices.
Stereotactic Radiosurgery for Brain Metastases from Human Epidermal Receptor 2 Positive Breast Cancer: An International, Multi-center Study
Pikis, Stylianos , Ross, Richard B. , Rusthoven, Chad G. , Langlois, Anne-Marie, Lee, Cheng-chia Lee, Peker, Selçuk , Samancı, Yavuz , Toss, Salem M., Niranjan, Ajay , Wei, Zhishuo , Lunsford, Dade, Sheehan, Jason P. , Mantziaris, Georgios , Protopapa, Maria , Tos, Salem M , Kowalchuk, Roman O. , Tripathi, Manjul , Langlois, Anne-Marie, Mathieu, David , Lee, Cheng‐Chia , Yang, Huai‐Che , Zhang, Michael , Braunstein, Steve

Mayo Clinic

No container title available | June 12, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4481085/v1 Get It

Abstract Purpose To report patient outcomes and local tumor control rates in a cohort of patients with biopsy-proven HER-2 positive breast cancer treated with stereotactic radiosurgery (SRS) for brain metastases (BM). Methods This international, retrospective, multicenter study, included 195 female patients with 1706 SRS-treated BM. Radiologic and clinical outcomes after SRS were determined and prognostic factors identified. Results At SRS, median patient age was 55 years [interquartile range (IQR) 47.6–62.0], and 156 (80%) patients had KPS ≥ 80. The median tumor volume was 0.1 cm3 (IQR 0.1–0.5) and the median prescription dose was 16 Gy (IQR 16–18). Local tumor control (LTC) rate was 98%, 94%, 93%, 90%, and 88% at six-, 12-, 24-, 36- and 60-months post-SRS, respectively. On multivariate analysis, tumor volume (p = < 0.001) and concurrent pertuzumab (p = 0.02) improved LTC. Overall survival (OS) rates at six-, 12-, 24-, 36-, 48-, and 60-months were 90%, 69%, 46%, 27%, 22%, and 18%, respectively. Concurrent pertuzumab improved OS (p = 0.032). In this patient subgroup, GPA scores ≥ 2.5 (p = 0.038 and p = 0.003) and rare primary tumor histologies (p = 0.01) were associated with increased and decreased OS respectively. Asymptomatic adverse radiation events (ARE) occurred in 27 (14.0%) and symptomatic ARE in five (2.6%) patients. Invasive lobular carcinoma primary (p = 0.042) and concurrent pertuzumab (p < 0.001) conferred an increased risk for overall but not for symptomatic ARE. Conclusion SRS affords effective LTC for selected patients with BM from HER-2 positive breast cancer. Concurrent pertuzumab improved LTC and OS with however an increased risk for overall but not symptomatic ARE.
Opening New Frontiers: Nedosiran Enables Kidney-Only Transplantation for Primary Hyperoxaluria Type 1: A Case Report
Nasir, Asma, Harvey, Elizabeth , Ávila-Casado, Carmen , Chan, Christopher T. , Mucsi, Istvan , Lieske, John C. , Lemaire, Mathieu J.

Mayo Clinic

Journal of the American Society of Nephrology | May 18, 2024 | Volume: 34 | Issue: 11S | Pages: 611-611

10.1681/asn.20233411s1611b Get It

Ciliopathy patient variants reveal organelle-specific functions for TUBB4B in axonemal microtubules
Dodd, Daniel O , Mechaussier, Sabrina , Yeyati, Patricia L. , McPhie, Fraser , Anderson, Jacob R. , Khoo, Chen Jing , Shoemark, Amelia , Gupta, Deepesh Kumar , Attard, Thomas, Zariwala, Maimoona A. , Legendre, Marie , Bracht, Diana , Gui, Miao , Parry, David , Black, Holly A. , Mitri-Frangieh, Rana, Faucon, Catherine, Kaplan, Josseline, Megaw, Roly , Mohamed, Mai A., Aitken, Stuart , Gautier, Philippe , Reinholt, Finn R., Hirst, Robert A. , O’Callaghan, Chris, Bottier, Mathieu , Escudier, Estelle , Crowley, Suzanne , Descartes, Maria , Kenia, Priti , Amiel, Jeanne , Bacci, Giacomo Maria , Calogero, Claudia , Palazzo, Viviana , Tiberi, Lucia , Blümlein, Ulrike, Rogers, Andrew, Wenger, David A. , Fulton, Anne B. , Rosenfeld, Margaret , Holm, Ingrid A., Quigley, Alan J. , Murphy, Laura C. , Cassidy, Diane M. , Kriegsheim, Alex von , Partnership, Scottish Genomes, Network, Undiagnosed Diseases, Murris, Marlène , Hogg, Claire , Macleod, Kenneth , Urquhart, Don S. , Unger, Stefan , Amselem, Serge , Leigh, Margaret W. , Knowles, Michael R. , Mitchison, Hannah M. , Rozet, Jean‐Michel , Mill, Pleasantine , Gupta, Deepesh K , Wallmeier, Julia , Fassad, Mahmoud R , Tennant, Peter A , Meynert, Alison , Wheway, Gabrielle , Fares-Taie, Lucas , Black, Holly A , Patel, Mitali , McKie, Lisa , Megaw, Roly , Aitken, Stuart , Gautier, Philippe , Heimdal, Ketil , Bottier, Mathieu , Escudier, Estelle , Crowley, Suzanne , Descartes, Maria , Jabs, Ethylin W , Bacci, Giacomo Maria , Calogero, Claudia , Tiberi, Lucia , Wambach, Jennifer A , Wegner, Daniel J , Fulton, Anne B , Kenna, Margaret , Quigley, Alan , Hall, Emma A , Murphy, Laura C , Cassidy, Diane M , von Kriegsheim, Alex , Pasquier, Laurent , Murris, Marlène S , Chalmers, James D , Hogg, Claire , Macleod, Kenneth A , Urquhart, Don S , Unger, Stefan , Aitman, Timothy J , Leigh, Margaret W , Omran, Heymut , Mitchison, Hannah M , Brown, Alan , Marsh, Joseph A , Ti, Shih-Chieh , Horani, Amjad , Rozet, Jean-Michel , Perrault, Isabelle , Mill, Pleasantine , Dodd, Daniel O. , Mechaussier, Sabrina , Gatsogiannis, Christos , Holm, Ingrid A., Partnership, Scottish Genomes, Network, Undiagnosed Diseases, Papon, Jean‐François , Pasquier, Laurent , Chalmers, James D. , Omran, Heymut , Welburn, Julie P. I.

Mayo Clinic

Science | April 25, 2024 | Volume: 384 | Issue: 6694 | Pages: No page available

10.1126/science.adf5489 | PMID 38662826 Get It

Tubulin, one of the most abundant cytoskeletal building blocks, has numerous isotypes in metazoans encoded by different conserved genes. Whether these distinct isotypes form cell type– and context-specific microtubule structures is poorly understood. Based on a cohort of 12 patients with primary ciliary dyskinesia as well as mouse mutants, we identified and characterized variants in the TUBB4B isotype that specifically perturbed centriole and cilium biogenesis. Distinct TUBB4B variants differentially affected microtubule dynamics and cilia formation in a dominant-negative manner. Structure-function studies revealed that different TUBB4B variants disrupted distinct tubulin interfaces, thereby enabling stratification of patients into three classes of ciliopathic diseases. These findings show that specific tubulin isotypes have distinct and nonredundant subcellular functions and establish a link between tubulinopathies and ciliopathies.
The past, present, and future of the brain imaging data structure (BIDS)
Markiewicz, Christopher J. , Bansal, Shashank , Bénar, Christian , Bertazzoli, Giacomo , Bhogawar, Suyash , Blair, Ross , Brooks, Teon L , Calhoun, Vince D. , Castelli, Filippo Maria , D’Ambrosio, Sasha , Hollander, Gilles de , Vega, Alejandro de la , Delorme, Arnaud , Earl, Eric , Feingold, Franklin , Flandin, Guillaume, Galassi, Anthony , Gallitto, Giuseppe , Ganz, Melanie , Gholam, James , Ghosh, Satrajit , Guidali, Giacomo , Handwerker, Daniel A. , Hardcastle, Nell , Innis, Robert B. , Ioanas, Horea-Ioan , Jahn, Andrew , Karakuzu, Agâh , Kincses, Bálint , Lau, Jonathan C. , Li, Xiangrui , Meisler, Steven L. , Mikkelsen, Mark E. , Nichols, Thomas E. , Ort, Eduard , Park, Patrick J., Pawlik, Mateusz , Pestilli, Franco , Pollonini, Luca , Rizzo, Gaia , Robbins, Kay A. , Rockhill, Alexander P. , Rogers, Christine , Rokem, Ariel , Rorden, Chris , Routier, Alexandre , Saborit-Torres, Jose Manuel , Schirner, Michael , Smith, Robert E. , Sprenger, Julia , Szinte, Martin , Thomas, Adam G. , Torabian, Sajjad, Voytek, Bradley , Calhoun, Vince D. , Poldrack, Russell A. , Appelhoff, Stefan , Ashar, Yoni K. , Auer, Tibor , Baillet, Sylvain , Beltrachini, Leandro , Bortoletto, Marta , Boudreau, Mathieu , Clement, Patricia , Cohen, Alexander L. , Cohen-Adad, Julien , Iglesia-Vayá, María de la , Devinsky, Orrin , Draschkow, Dejan , Duff, Eugene Paul , DuPré, Elizabeth , Estéban, Oscar , Gau, Rémi , Ghosh, Satrajit S , Giacomel, Alessio , Gillman, Ashley , Gleeson, Padraig , Gramfort, Alexandre , Guay, Samuel , Halchenko, Yaroslav O. , Herholz, Peer , Hermes, Dora , Honey, Christopher John , Keator, David B. , Kiar, Gregory , Laird, Angela R. , Lazari, Alberto , Legarreta, Jon Haitz , Li, Adam , Love, Bradley C. , Lu, Hanzhang , Marcantoni, Eleonora , Maumet, Camille , Mazzamuto, Giacomo , Mutsaerts, Henk , Nikolaidis, Aki , Nilsonne, Gustav , Niso, Guiomar , Nørgaard, Martin Agge , Okell, Thomas W. , Oostenveld, Robert , Pernet, Cyril R , Petr, Jan , Phillips, Christophe L. M. , Poline, Jean‐Baptiste , Raamana, Pradeep Reddy , Ritter, Petra , Salo, Taylor , Spisák, Tamás , Swann, Nicole C. , Takerkart, Sylvain , Thirion, Bertrand , Varoquaux, Gaël , Welzel, Julius , Wilson, Martin , Yarkoni, Tal , Gorgolewski, Krzysztof J.

Mayo Clinic

Imaging Neuroscience | February 20, 2024 | Volume: 2 | Issue: No issue available | Pages: No page available

10.1162/imag_a_00103 | PMID 39308505 Get It

Abstract The Brain Imaging Data Structure (BIDS) is a community-driven standard for the organization of data and metadata from a growing range of neuroscience modalities. This paper is meant as a history of how the standard has developed and grown over time. We outline the principles behind the project, the mechanisms by which it has been extended, and some of the challenges being addressed as it evolves. We also discuss the lessons learned through the project, with the aim of enabling researchers in other domains to learn from the success of BIDS.
The relevance of biologically effective dose for pain relief and sensory dysfunction after Gamma Knife radiosurgery for trigeminal neuralgia: an 871-patient multicenter study
Warnick, Ronald E. , Adam, Elizabeth , Iorio‐Morin, Christian , Leduc, William, Hamel, Andréanne, Johnson, Sarah E. , Bydon, Mohamad , Niranjan, Ajay , Lunsford, L. Dade , Wei, Zhishuo , Waite, Kaitlin, Jose, Shalini, Peker, Selçuk , Samanci, Mustafa Yavuz, Tek, Ece, Pikis, Stylianos , Sheehan, Jason P. , Kumar, Narendra , Bernstein, Kenneth , Ahorukomeye, Peter , Kshettry, Varun R. , Hernández, Wenceslao, Urgošík, Dušan, Lee, John Y. K., Patel, Samir , Kusyk, Dorian , Shepard, Matthew J., Samancı, Yavuz , Paddick, Ian , Mathieu, David , Mantziaris, Georgios , Tripathi, Manjul , Alzate, Juan Diego , Speckter, Herwin , Liščák, Roman , Yang, Andrew I. , Kondziolka, Douglas

Mayo Clinic

Journal of Neurosurgery | February 17, 2024 | Volume: 141 | Issue: 2 | Pages: 461-473

10.3171/2023.12.jns231569 | PMID 38364220 Get It

OBJECTIVE Recent studies have suggested that biologically effective dose (BED) is an important correlate of pain relief and sensory dysfunction after Gamma Knife radiosurgery (GKRS) for trigeminal neuralgia (TN). The goal of this study was to determine if BED is superior to prescription dose in predicting outcomes in TN patients undergoing GKRS as a first procedure. METHODS This was a retrospective study of 871 patients with type 1 TN from 13 GKRS centers. Patient demographics, pain characteristics, treatment parameters, and outcomes were reviewed. BED was compared with prescription dose and other dosimetric factors for their predictive value. RESULTS The median age of the patients was 68 years, and 60% were female. Nearly 70% of patients experienced pain in the V2 and/or V3 dermatomes, predominantly on the right side (60%). Most patients had modified BNI Pain Intensity Scale grade IV or V pain (89.2%) and were taking 1 or 2 pain medications (74.1%). The median prescription dose was 80 Gy (range 62.5–95 Gy). The proximal trigeminal nerve was targeted in 77.9% of cases, and the median follow-up was 21 months (range 6–156 months). Initial pain relief (modified BNI Pain Intensity Scale grades I–IIIa) was noted in 81.8% of evaluable patients at a median of 30 days. Of 709 patients who achieved initial pain relief, 42.3% experienced at least one pain recurrence after GKRS at a median of 44 months, with 49.0% of these patients undergoing a second procedure. New-onset facial numbness occurred in 25.3% of patients after a median of 8 months. Age ≥ 63 years was associated with a higher probability of both initial pain relief and maintaining pain relief. A distal target location was associated with a higher probability of initial and long-term pain relief, but also a higher incidence of sensory dysfunction. BED ≥ 2100 Gy2.47 was predictive of pain relief at 30 days and 1 year for the distal target, whereas physical dose ≥ 85 Gy was significant for the proximal target, but the restricted range of BED values in this subgroup could be a confounding factor. A maximum brainstem point dose ≥ 29.5 Gy was associated with a higher probability of bothersome facial numbness. CONCLUSIONS BED and physical dose were both predictive of pain relief and could be used as treatment planning goals for distal and proximal targets, respectively, while considering maximum brainstem point dose < 29.5 Gy as a potential constraint for bothersome numbness.
Basics of Point-of-Care Lung Ultrasonography
Buda, Natalia , Mendrala, Konrad , Skoczyński, Szymon , Pasquier, Mathieu , Mazur, Piotr , García, Elena Hernández, Darocha, Tomasz , Garcia, Elena, Mazur, Piotr K , Garcia, Elena

Mayo Clinic

New England Journal of Medicine | November 22, 2023 | Volume: 389 | Issue: 21 | Pages: No page available

10.1056/nejmvcm2108203 | PMID 37991857 Get It

Local control and survival after stereotactic radiosurgery for colorectal cancer brain metastases: an international multicenter analysis
Singh, Raj , Legarreta, Aimé Parra , Bowden, Greg , Perlow, Haley K. , Elhamdani, Shahed, Shepard, Matthew J., Liang, Yun , Nabeel, Ahmed M. , Reda, Wael A. , Tawadros, Sameh R. , Eldin, Reem Emad, Elazzazi, Ahmed Hesham, Warnick, Ronald E. , Gozal, Yair M., Daly, Megan, McShane, Brendan, Addis-Jackson, Marcel, Karthikeyan, Gokul, Franzini, Andrea , Hess, Judith, Templeton, Kelsey, Zhang, Xiaoran , Wei, Zhishuo , Pikis, Stylianos , Mantziaris, Georgios , Peker, Selçuk , Samancı, Yavuz , Chiang, Veronica , Kersh, Charles R. , Lee, Cheng-chia, Niranjan, Ajay , Hadjipanayis, Constantinos G., Lunsford, L. Dade , Sheehan, Jason P. , Mantziaris, Georgios , Perlow, Haley K , Bin-Alamer, Othman , Abou‐Al‐Shaar, Hussam , Mallela, Arka N. , Mathieu, David , Palmer, Joshua D. , Elhamdani, Shahed, Abdelkarim, Khaled , El-Shehaby, Amr M. N. , Eldin, Reem M. Emad, Karthikeyan, Gokul, Smith, Sian K. , Picozzi, Piero , Kaisman‐Elbaz, Tehila , Yang, Huai‐Che , Šimonová, Gabriela , Liščák, Roman , Trifiletti, Daniel M.

Mayo Clinic

Journal of Neurosurgery | November 11, 2023 | Volume: 140 | Issue: 5 | Pages: 1233-1242

10.3171/2023.8.jns231231 | PMID 37948682 Get It

OBJECTIVE The goal of this study was to characterize local tumor control (LC), overall survival (OS), and safety of stereotactic radiosurgery for colorectal brain metastasis (CRBM). METHODS Ten international institutions participating in the International Radiosurgery Research Foundation provided data for this retrospective case series. This study included 187 patients with CRBM (281 tumors), with a median age of 62 years and 56.7% being male. Most patients (53.5%) had solitary tumors, although 10.7% had > 5 tumors. The median tumor volume was 2.7 cm3 (IQR 0.22–8.1 cm3), and the median margin dose was 20 Gy (IQR 18–22 Gy). RESULTS The 3-year LC and OS rates were 72% and 20%, respectively. Symptomatic adverse radiation effects occurred in 1.6% of patients. In the multivariate analysis, age > 65 years and tumor volume > 4.0 cm3 were significant predictors of tumor progression (hazard ratio [HR] 2.6, 95% CI 1.4–4.9; p = 0.003 and HR 3.4, 95% CI 1.7–6.9; p < 0.001, respectively). Better performance status (Karnofsky Performance Scale score > 80) was associated with a reduced risk of tumor progression (HR 0.38, 95% CI 0.19–0.73; p = 0.004). Patient age > 62 years (HR 1.6, 95% CI 1.1–2.3; p = 0.03) and the presence of active extracranial disease (HR 1.7, 95% CI 1.1–2.4; p = 0.009) were significantly associated with worse OS. CONCLUSIONS Stereotactic radiosurgery offers a high LC rate and a low rate of symptomatic adverse radiation effects for the majority of CRBMs. The OS and LC favored younger patients with high functional performance scores and inactive extracranial disease.
Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome
Sıva, Aksel , Landes-Château, Cassandre , Mondot, Lydiane, Papeix, Caroline , Thouvenot, Éric , Labauge, Pierre, Durand‐Dubief, Françoise , Page, Emmanuelle Le , Terzi, Murat , Derache, Nathalie, Bourre, Bertrand , Hoepner, Robert , Karabudak, Rana , Ciron, Jonathan , Wiertlewski, Sandrine, Turan, Ömer Faruk , Yucear, Nur, Cohen, Mikaël , Azevedo, Christina , Kantarci, Orhun H. , Pelletier, Daniel , Group, TERIS Study, Branger, Pierre , Abrous, Mouloud, Petit, Julie, Gelet, Céline, Russello, Mélanie, Gaultier, Alina, Frère, Fabienne Le, Callier, Céline, Caillon, Cynthia, Gueydan, Eglantine, Louapre, Céline , Galanaud, Damien , Ungureanu, Aurelian , Coudoin, Sylvie, Hébant, Benjamin , Gerard, Emmanuel, Vimont, Christine, Bonneville, Fabrice , Freitas, Noellie, Kilic, Erhan , Destan, Sena, Friedli, Christoph , Wagner, Franca , Weber, Lea , Tchoubar, Annaig, Dumont, Émilie , Eryilmaz, Asli, Roman, Tanguy, Pelletreau, Christopher, Grateau, Aurélie, Mathieu, Yanica, Yaïche, Sarhan, Rintelen, Felix, Firmino, Isabel, Chastenier, Aymeric De, Gheribenblidia, Amel, Zeydan, Burcu , Siva, Aksel , Zeydan, Burcu , Thouvenot, Eric , Ciron, Jonathan , Durand-Dubief, Françoise , Cohen, Mikaël , Lebrun‐Frénay, Christine , Sormani, Maria Pia , Mondot, Lydiane , Bovis, Francesca , Vermersch, Patrick , Labauge, Pierre , Efendi, Hüsnü , Bourre, Bertrand , Seze, Jerome De , Clavelou, Pierre , Okuda, Darin T. , Group, TERIS Study, Zéphir, Hélène , Vukusic, Sandra , Carra‐Dallière, Clarisse , Ayrignac, Xavier , Laplaud, David , Biotti, Damien , Duman, Taşkın , Tütüncü, Melih , Uygunoğlu, Uğur , Şen, Sedat , Weber, Lea, Eryılmaz, Aslı

Mayo Clinic

JAMA Neurology | August 21, 2023 | Volume: 80 | Issue: 10 | Pages: 1080

10.1001/jamaneurol.2023.2815 | PMID 37603328 Get It

Importance Radiologically isolated syndrome (RIS) represents the earliest detectable preclinical phase of multiple sclerosis (MS) punctuated by incidental magnetic resonance imaging (MRI) white matter anomalies within the central nervous system. Objective To determine the time to onset of symptoms consistent with MS. Design, Setting, and Participants From September 2017 to October 2022, this multicenter, double-blind, phase 3, randomized clinical trial investigated the efficacy of teriflunomide in delaying MS in individuals with RIS, with a 3-year follow-up. The setting included referral centers in France, Switzerland, and Turkey. Participants older than 18 years meeting 2009 RIS criteria were randomly assigned (1:1) to oral teriflunomide, 14 mg daily, or placebo up to week 96 or, optionally, to week 144. Interventions Clinical, MRI, and patient-reported outcomes (PROs) were collected at baseline and yearly until week 96, with an optional third year in the allocated arm if no symptoms have occurred. Main outcomes Primary analysis was performed in the intention-to-treat population, and safety was assessed accordingly. Secondary end points included MRI outcomes and PROs. Results Among 124 individuals assessed for eligibility, 35 were excluded for declining to participate, not meeting inclusion criteria, or loss of follow-up. Eighty-nine participants (mean [SD] age, 37.8 [12.1] years; 63 female [70.8%]) were enrolled (placebo, 45 [50.6%]; teriflunomide, 44 [49.4%]). Eighteen participants (placebo, 9 [50.0%]; teriflunomide, 9 [50.0%]) discontinued the study, resulting in a dropout rate of 20% for adverse events (3 [16.7%]), consent withdrawal (4 [22.2%]), loss to follow-up (5 [27.8%]), voluntary withdrawal (4 [22.2%]), pregnancy (1 [5.6%]), and study termination (1 [5.6%]). The time to the first clinical event was significantly extended in the teriflunomide arm compared with placebo, in both the unadjusted (hazard ratio [HR], 0.37; 95% CI, 0.16-0.84; P = .02) and adjusted (HR, 0.28; 95% CI, 0.11-0.71; P = .007) analysis. Secondary imaging end point outcomes including the comparison of the cumulative number of new or newly enlarging T2 lesions (rate ratio [RR], 0.57; 95% CI, 0.27-1.20; P = .14), new gadolinium-enhancing lesions (RR, 0.33; 95% CI, 0.09-1.17; P = .09), and the proportion of participants with new lesions (odds ratio, 0.72; 95% CI, 0.25-2.06; P = .54) were not significant. Conclusion and Relevance Treatment with teriflunomide resulted in an unadjusted risk reduction of 63% and an adjusted risk reduction of 72%, relative to placebo, in preventing a first clinical demyelinating event. These data suggest a benefit to early treatment in the MS disease spectrum. Trial Registration ClinicalTrials.gov Identifier: NCT03122652